Kala Bio Files 2024 10-K, Details Securities Purchase Agreements
Ticker: KALA · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1479419
Sentiment: neutral
Topics: 10-K, financing, biotech
TL;DR
KALA 2024 10-K filed. Shows major stock deals in late 2024. Raising cash.
AI Summary
Kala Bio, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company reported significant financial activities, including a Third Securities Purchase Agreement on December 29, 2024, and a Second Securities Purchase Agreement on June 26, 2024. These agreements likely relate to capital raising efforts to fund its operations and development pipeline.
Why It Matters
This filing provides investors with a comprehensive overview of Kala Bio's financial health and strategic transactions for the past fiscal year, including key capital-raising events.
Risk Assessment
Risk Level: medium — Biotech companies like Kala Bio are inherently risky due to the high failure rate of drug development and regulatory hurdles.
Key Numbers
- 20241231 — Fiscal Year End (Reporting period for the 10-K)
- 20250331 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- KALA BIO, Inc. (company) — Filer of the 10-K
- December 31, 2024 (date) — Fiscal year end
- December 29, 2024 (date) — Date of Third Securities Purchase Agreement
- June 26, 2024 (date) — Date of Second Securities Purchase Agreement
- January 10, 2023 (date) — Date of Shelf 2020 Underwritten Offering
FAQ
What was the primary purpose of the Third Securities Purchase Agreement on December 29, 2024?
The filing indicates a Third Securities Purchase Agreement occurred on December 29, 2024, suggesting it was a capital-raising event to fund operations or development, though specific details are not provided in this excerpt.
How much capital did Kala Bio raise through its securities purchase agreements in 2024?
This excerpt does not provide the specific dollar amounts raised in the Third Securities Purchase Agreement (December 29, 2024) or the Second Securities Purchase Agreement (June 26, 2024).
What is Kala Bio's main business focus?
Kala Bio, Inc. is classified under Pharmaceutical Preparations [2834] according to its SIC code, indicating a focus on developing and manufacturing pharmaceutical products.
When was Kala Bio formerly known as Kala Pharmaceuticals, Inc. and when did the name change?
Kala Bio, Inc. was formerly known as Kala Pharmaceuticals, Inc., and the date of the name change was December 23, 2009.
What other significant financing event occurred in early 2023?
A Shelf 2020 Underwritten Offering is noted with a date of January 10, 2023, indicating a past financing activity.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding KALA BIO, Inc. (KALA).